| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Freeline Therapeutics and Checkmate Pharma Make Opening IPO Moves | Frank Vinluan | 07/21/20 | Europe |
| Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact | Frank Vinluan | 05/27/20 | San Francisco |
| Takeda Pays Turnstone $120M to Start Alliance on Viral Cancer Therapies | Frank Vinluan | 12/19/19 | New York |
| Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck | Frank Vinluan | 12/04/19 | San Francisco |
| Gilliland to Step Down as Head of Fred Hutch in 2020 | Jeff Buchanan | 09/17/19 | Seattle |
| At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More | Ben Fidler | 09/09/19 | National |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More | Ben Fidler | 07/26/19 | National |
| Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck | Ben Fidler | 07/24/19 | New York |
| Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More | Frank Vinluan | 06/21/19 | National |
| Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal | Ben Fidler | 06/10/19 | Boston |
| ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More | Alex Lash | 06/05/19 | National |
| Immunotherapy Is Now Here For Breast Cancer. What Are Its Prospects? | Ben Fidler | 05/29/19 | National |
| Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More | Alex Lash | 05/24/19 | National |
| Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More | Frank Vinluan | 04/26/19 | National |
| AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results | Ben Fidler | 04/03/19 | National |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Bayer Snaps Up Rights to Two Cancer Drugs from Lilly’s $8B Loxo Deal | Frank Vinluan | 02/15/19 | Indiana |
| Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More | Alex Lash | 02/15/19 | National |
| Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter | Ben Fidler | 01/16/19 | National |
| In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B | Ben Fidler | 01/03/19 | National |
| Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More | Alex Lash | 12/21/18 | National |
| 15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) | Ben Fidler | 12/18/18 | National |
| Genetic Medicine: FDA OKs 2nd Cancer Drug That Targets DNA, Not Tissues | Ben Fidler | 11/26/18 | National |
| Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More | Frank Vinluan | 11/16/18 | National |
| Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End | Ben Fidler | 10/19/18 | National |
| A Year Early, Merck Touts Good Kidney Cancer News to Push Rival BMS | Alex Lash | 10/18/18 | New York |
| Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up | Ben Fidler | 10/12/18 | New York |
| Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More | Frank Vinluan | 09/14/18 | National |
